Exelixis is stretching cabozantinib’s cash-flow runway to 2030 while racing zanzalintinib toward a first launch that could turn a one-franchise biotech into a multi-franchise oncology platform.
Overview
Q1 2026 confirms Exelixis’ ability to sustain profitable growth while funding a major pipeline and portfolio transition. The company reported $610.8M revenue (up YoY, modestly below consensus) and $210.5M GAAP net income ($0.79/sh), with adjusted EPS of $0.87 beating expectations and extending a pattern of earnings outperformance. FY2025 revenue reached ~$2.32B (+7% YoY), driven by 17% growth in U.S. cabozantinib net product revenues, and marked the ninth consecutive year of operating profitability—rare durability for mid-cap biotech. Strategically, Exelixis is defending and expanding cabozantinib (RCC leadership; rapidly scaling NET indication) while preparing for a potential zanzalintinib launch in metastatic colorectal cancer (PDUFA Dec 3, 2026) supported by positive STELLAR-303 outcomes. The risk around the 2026 core patent expiry is materially mitigated by court-upheld malate salt patents through Jan 2030, providing a longer runway to establish the next franchise. Meanwhile, aggressive buybacks and performance-linked compensation suggest strong alignment and confidence in a pipeline-driven re-rating.